Systemic treatment for HER2-positive breast cancer patients can include tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and antibody drug conjugates (ADCs), as well as combinations of chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.